Pair page
AOD-9604 with Tesamorelin
Mechanism-tag overlap and published literature for AOD-9604 and Tesamorelin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
hgh-c-terminal-fragment-lipolytic
fda-approved-ghrh-analogvisceral-adiposity
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying AOD-9604 and Tesamorelin have published these mechanism-level observations. Not a co-administration recommendation.
Stabilized GHRH analog with FDA approval for HIV-associated lipodystrophy. Stronger visceral-fat-reduction signal than AOD-9604 alone. Used as an alternative rather than a stack in practice.
Quick facts
AOD-9604
Tesamorelin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2014 | AOD-9604 | Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014;95(1):53-66. PMID: 24105257. (Obesity pharmacotherapy review discussing AOD-9604's Phase 2b failure.) PMID 24105257 | human trial, Phase 2 |
| 2013 | AOD-9604 | Kasim-Karakas SE, Cunningham WM, Tsodikov A. Relation of nutrients and hormones in polycystic ovary syndrome. Obesity Pharmacotherapy: Current Perspectives and Future Directions. 2013. PMC: PMC3584306. (Review describing AOD-9604 Phase 2 results and 2007 program termination.) | human trial, Phase 2 |
| 2007 | AOD-9604 | Metabolic Pharmaceuticals Ltd. Phase 2b OPTIONS clinical trial results: AOD9604 24-week randomized placebo-controlled trial in 536 obese adults. 2007. (Failed primary endpoint. Publicly disclosed in biotech press; led to obesity program termination.) | human trial, Phase 2 |
| 2004 | AOD-9604 | Metabolic Pharmaceuticals Ltd. Phase 2 OBESITY clinical trial results: AOD9604 12-week dose-ranging study in obese adults (0.25, 0.5, 1 mg/day). 2004-2005. (Positive Phase 2 signal at 1 mg/day: 2.6 kg weight loss vs 0.8 kg placebo.) | human trial, Phase 2 |
| — | AOD-9604 | ClinicalTrials.gov. Metabolic Pharmaceuticals AOD9604 Phase 2 / Phase 2b obesity trials registration and results. clinicaltrials.gov. (Trial documentation.) | human trial, Phase 2 |
| 2015 | AOD-9604 | Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. PMID: 26132939. (Comparator: GLP-1 agonist obesity therapeutic evidence — the modern standard AOD-9604 fails to meet.) PMID 26132939 | human trial |
| 2012 | AOD-9604 | The effect of AOD9604 on weight loss in obese adults: Results of a randomized, double-blind, placebo-controlled, multicenter study (referenced in Chugh 2012 review). | human trial |
| 2012 | AOD-9604 | Chugh PK, Sharma S. Recent advances in the pathophysiology and pharmacological treatment of obesity. J Clin Pharm Ther. 2012;37(5):525-535. DOI: 10.1111/j.1365-2710.2012.01347.x. (Places AOD-9604 in obesity-pharmacotherapy context.) | human study |
| 2001 | AOD-9604 | Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 117132… PMID 11713213 | preclinical, in vivo |
| 2001 | AOD-9604 | Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1586-1592. PMID: 11673763. (Both hGH and AOD-9604 reduce body weight; AOD does not interact… PMID 11673763 | preclinical, in vivo |
| 2000 | AOD-9604 | Ng FM, Sun J, Sharma L, Libinaki R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11044801. (Foundational mechanistic characterization.) PMID 11044801 | mechanism / discovery |
| — | AOD-9604 | Safety review in the Journal of Obesity & Food Metabolism aggregating six RCTs of AOD-9604 (>900 subjects). (Comprehensive safety database summary.) | review |
| 2010 | Tesamorelin | Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind place… PMID 20101189 | human trial, Phase 3 |
| — | Tesamorelin | ClinicalTrials.gov. NCT00123253, NCT00435136 (Phase 3 registration); NCT01263717 (JAMA liver fat); NCT02196831 (Lancet HIV NAFLD); NCT00675506 (Arch Neurol cognition). | human trial, Phase 3 |
| 2019 | Tesamorelin | Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID: 31611038. PMID 31611038 | human trial |
| 2014 | Tesamorelin | Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID: 25038357. PMID 25038357 | human trial |
| 2005 | Tesamorelin | Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-1287. PMID: 16052083. PMID 16052083 | human trial |
| 2004 | Tesamorelin | Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized, controlled trial. JAMA. 2004;292(2):210-218. PMID: 15249570. PMID 15249570 | human trial |
| 2012 | Tesamorelin | Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429.… PMID 22869065 | human study |
| 2011 | Tesamorelin | Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. Clin Infect Dis. 2011;53(11):1150-1158. PMID: 22016502. PMID 22016502 | human study |
| 2008 | Tesamorelin | Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. PMID: 18690162. PMID 18690162 | human study |
| 2007 | Tesamorelin | Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338. PMID 18057338 | human study |
| 2011 | Tesamorelin | Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. PMID: 21668043. PMID 21668043 | review |
| 2026 | Tesamorelin | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have AOD-9604 and Tesamorelin been studied together?
Researchers have published mechanistic-level co-administration discussion of AOD-9604 and Tesamorelin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do AOD-9604 and Tesamorelin share?
AOD-9604 and Tesamorelin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of AOD-9604 and Tesamorelin?
AOD-9604: Not approved (research). Tesamorelin: Approved (2010). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on AOD-9604 and Tesamorelin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the AOD-9604 profile and the Tesamorelin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026